Summary Meta-analysis of the published results from 54 randomised controlled trials of adjuvant chemotherapy in head and neck cancer suggests that chemotherapy might increase absolute survival by 6.5% (95% confidence interval 3.1-9.9%). The odds ratio in favour of chemotherapy is 1.37 (95% confidence interval 1.24-1.5). Single-agent chemotherapy given synchronously with radiotherapy increased survival by 12.1% (95% confidence interval 5-19%). The benefit from neoadjuvant chemotherapy was less: a rate difference of 3.7% (95% confidence interval 0.9-6.5%). The results suggest that the investigation of optimal agents and scheduling for synchronous radiotherapy and chemotherapy might still be important in clinical trials in head and neck cancer.
Attitudes towards cytotoxic chemotherapy for squamous carcinomas of the head and neck range from enthusiasm (Dimery and Hong, 1993) to disdain (Tannock and Browman, 1986; Taylor, 1987) . Response rates to chemotherapy are high, but this responsiveness does not appear to translate into durable benefit in terms of survival. Recent metaanalyses of adjuvant chemotherapy for squamous cell carcinoma of the head and neck failed to show any benefit from such treatment (Stell and Rawson, 1990; Stell, 1992) . However, several randomised trials published subsequently have been reported as showing benefit from adding chemotherapy to standard therapy. In order better to define the possible role for chemotherapy and to suggest possibly fruitful avenues for exploration, a further meta-analysis of published randomised clinical studies of adjuvant chemotherapy in head and neck cancer has been performed.
The primary purpose of this overview was to discover whether the addition of chemotherapy to definitive standard therapy improved survival in patients with cancer of the head and neck. Secondary objectives included an assessment of whether the timing of chemotherapy, before, during or after standard therapy, was important; a specific assessment of the effectiveness of platinum/5-fluorouracil regimens; an evaluation of single-agent chemotherapy given synchronously with radiotherapy; an assessment of the effect of chemotherapy upon locoregional control rates; an assessment of the effect of chemotherapy upon the occurrence of distant metastases.
Materials and methods
A structured search was conducted to identify randomised clinical trials of chemotherapy in head and neck cancer. A trial was suitable for inclusion if it fulfilled the following criteria. * published between January 1963 and August 1993; * allocation of treatment was said to be randomised; * there was a control arm in which patients did not receive chemotherapy; * Results were available for survival, disease-free survival or local control.
Abstracts as well as published papers were acceptable. If the same data had been published more than once, the most recent data were used. Several complementary search procedures were used: MEDLINE search; a review of the Physicians' Data Query (Silver Platter) clinical trials data-base; review of the relevant sections in the two available volumes of Randomized Trials in Cancer: A Critical Review by Sites (Cachin, 1978; Dodion et al., 1986 ); a systematic review of every volume of the published proceedings of the American Society of Clinical Oncologists from 1979 to 1993.
The data were abstracted from photocopies of the original publications and entered onto a spreadsheet (Excel 4.0). Trials were classified as follows: * neoadjuvant, chemotherapy given before definitive therapy;
* synchronous, chemotherapy given synchronously with radiotherapy; * post-definitive, chemotherapy given after definitive therapy. Some trials combined more than one of the above components; such trials were classified according to the earliest appearance of chemotherapy in the protocol. For example, a trial involving two courses of chemotherapy then surgery, then maintenance chemotherapy would simply be classified as neoadjuvant.
The analysis was performed on published data: no attempt was made to obtain data on individual patients. The times at which survival was reported varied between studies. The maximum survival interval available was used with an upper limit of 5 years. Survival data, therefore, apply only to the particular time point available for each trial. No allowance has been made for the inevitable censoring within trials or for differential censoring between trials. Wherever possible, the raw numbers were used: in the absence of such data the numbers were estimated from the published survival curves. The values were obtained by applying a set square to the survival curve at the specified time point, reading off the percentage surviving, and thereby calculating, from the total number randomised to that group, the absolute number of survivors. The validity of the abstracted data was assessed by repeated cross-checking and also, where possible, by comparison with the data presented in previous overviews (Stell and Rawson, 1990; Stell, 1992) . Of necessity, however, the data used are crude and, at best, approximate.
The estimation of the number of events in the control and experimental arms is, when there is no access to data on individual patients, subject to a number of possible biases. Two possible sources of bias are: differential censoring between the two arms of the trial so that the denominator in the experimental arm is proportionally lower than that in the control arm, thereby exaggerating the benefit of the experimental therapy; and systematic errors in extracting the data from published reports so that the survival rate is consistently overestimated in the experimental arm and consistently underestimated in the control arm. Sensitivity 
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Over 150 randomised trials in head and neck cancer were identified. Of these, 54 fulfilled the criteria for inclusion in this meta-analysis. These are summarisd in Table I . The time at which the end point was assessed was unspecified in 9/54 studies and was less than 24 months in a further nine stuie. The graphial assessment of homogeneity for the 51 comparisons of suvival data is shown in Figure 1 . The trials appear to be heterogeneous, and this is confirmed by the Q-statistic of 111.1 which, on 50 degrees of freedom, corresponds to a P-value of <10-': we can reject the null hypothesis of homogeneity among trials. This degree of inh oeneity is unsurpsing given the wide variations in eigibility criteria and times chosen for the estiation of survival.
The data for all 51 comparisons are presented in Table H . The odds ratio, rate difference, x2 for difference in survival between treatment and control arms and P-value calulated from x2 are shown for each trial. Using P<0.05 as the criterion for a positive result, only nine studies were positive by both the rate difference and odds ratio methods; 39 were negative by both methods and three were positive by the odds ratio method but negative by the rate difference method. For trials defined as non-sgnficant (P>0.05). the probability that the result is a false negative has been shown for a 25% relative increase in survival in the chemotherapy arm. A relative increase in survival of 25% corresponds to an increase, in absolute terms, from 40% to 50% or from 16% to 20%. Of the 42 negative comparisons, 14 had a >25% probability of being false negative and five had a probability of being false negative of >50%.
The 95% confidence limits of the rate differences are shown in Figure 2 Trial   4  39  48  57  6  9  15  17  18  24  26  27  28  29  31  32  34  35  36  37  41  45  47  49  51  52  14a  14b  23a  23b  7b  2  3   5   8  10   11   12  13  16  20  25  30  40  44  53  55  56  42a  7a Type p p p p p n n n n n n n n n n n n n n n n n n n n n n n n n n n 68  82  332  63  292  303  40  56  34  84  58  175  199  32  104  155  313  40  209  136  157  577  63  222  120  150  116 Even adding 20 negative studies with survival rates of 33% in each arm and 1200 patients randomised in each trial, the overall x2 would still be 9.71 (P<0.005). No single study was unduly influential. Eliminating significant studies in sequence did not affect the conclusions. For example, even if the 11 most significant studies were eliminated completely, the overall X2 was still 5.29 (P = 0.021).
The results from the sensitivity analyses dealing with possible bias in data publication and extraction are shown in Figure 4 . The robustness of the conclusion is sensitive to this type of bias. A constant bias of 5% produces results similar to a bias varying randomly for each trial between 0 and 10%; this again suggests that no one trial is unduly influential.
The subgroup analyses suggest that single-agent chemotherapy given with radiotherapy is particularly effective -rate difference 13.7% (95% CI 6.1-21.3%) -but neoadjuvant chemotherapy is somewhat less effective -rate difference 3.9% (95% CI 1.1-6.7%). Platinum/5-FU regimens do not appear to be outstandingly effective -rate difference 5.4% (95% CI 0.1-10%). The data on local control are consistent This overview of trials of adjuvant chemotherapy in head and neck cancer suggests that chemotherapy might improve survival and that this improvement is more apparent for single-agent chemotherapy given synchronously with radiotherapy. Since two previous meta-analyses (Stell and Rawson, 1990; Stell, 1992) failed to show benefit from chemotherapy, the discrepancies between these previous analyses and the current results must be explained. Stell and Rawson's first analysis (1990) included 23 trials, and the updated analysis added five newer trials to give a total of 28 trials (Stell, 1992 Cumulative meta-analyses, and the current study could be regarded as the third in a sequence for head and neck cancer, can be useful for the prompt detection of therapeutic advances. Experience from trials of treatment for myocardial infarction showed that, although early overviews were negative, the accumulation of evidence eventually favoured active therapy (Antman et al., 1992; Lau et al., 1992) .
The main disadvantage of the present analysis is that it is based upon the published literature rather than upon data from individual patients. This raises problems with the (Stewart and Parmar, 1993) . The inability to use a constant time point for survival, for example, introduces potentially serious bias since the survival at arbitrary time points does not, and cannot, represent the overall shape of the survival curve. The sensitivity analyses clearly show that the overall conclusion of this overview is sensitive to this type of bias. The only solution is to perform a per-patient analysis, and such a study is currently under way (MKB Parmar, 1994, personal communication). Unfortunately, it will be at least 2 years until the results are published; in the meantime literature-based analysis, with all its imperfections, will have to suffice.
The present overview suggests that the largest gains, in terms of survival, may be obtained by using chemotherapy synchronously with radiotherapy. The demonstration that gains from neoadjuvant therapy are relatively modest compared with the benefits from synchronous therapy is provocative and, if true, would require an explanation consistent with the basic biology of squamous carcinoma of the head and neck. Squamous carcinomas of the head and neck have high cell loss factors: 90% of cells produced by mitosis of clonogenic cells may be lost through exfoliation and migration. Relatively modest killing of clonogens will, through the effects of cell loss, produce rapid shrinkage of tumour. This rapid regression, is, however, virtually an epiphenomenonalbeit a gratifying one.
The ultimate outcome is dictated by those clonogenic cells which are not lost and, in particular, their resistance to therapy. Because of cell loss, a clinically apparent tumour is genetically old, a 2 cm squamous cell carcinoma of the head and neck is perhaps 600-1000 generations old. In the absence of cell loss it would take only 30-40 generations to reach this size. The chance of a mutation emerging that confers drug resistance increases with each generation. There is a high probability that, at diagnosis, even small tumours of the head and neck will contain clonogenic cells which are, de novo, resistant to cytotoxic drugs. Cell loss can therefore explain both the initial responsiveness and the ultimate resistance to chemotherapy of these tumours. Accelerated repopulation of clonogenic cells in tumours may compromise the effectiveness of radiotherapy for head and neck cancers (Withers et al., 1988) . Neoadjuvant chemotherapy, by providing the stimulus for such repopulation several weeks before the start of radiotherapy, might exacerbate this problem. With synchronous chemotherapy, the problem of such treatment-induced perturbations does not apply.
The data on the effects of chemotherapy upon distant metastasis are conflicting. This partly reflects the fact that distant metastases are an uncommon cause of treatment failure in head and neck cancer. The majority of patients who die do so from local regional failure. The inability of chemotherapy to prevent distant metastasis may therefore be more apparent than real.
An overview has two main purposes: firstly to suggest what, on the basis of data from clinical trials, might be defined as reasonable current practice; secondly, to provide a stimulus to further studies. Primary treatment with chemotherapy may provide useful relief of symptoms in patients treated palliatively, but there is little justification for the routine use of neoadjuvant chemotherapy in head and neck cancer. The claim, from the Veterans Administration study (The Department of Veterans Affairs Laryngeal Cancer Study , that neoadjuvant chemotherapy offers the possibility of avoiding mutilating surgery in head and neck cancer is controversial since that study, by virtue of its design, was unable to provide any evidence that chemotherapy plus radiotherapy was any better than radiotherapy alone.
The data presented here suggest that we might put less effort into neoadjuvant studies and return to a more detailed investigation of the effectiveness of single-agent chemotherapy given synchronously with radiotherapy. Such treatment is simple and inexpensive. The survival benefit may be genuine: the next questions are what are the costs of such benefit in terms of excess morbidity and which is the best drug to use? Future trials will need to collect adequate data, both objective and subjective, on the toxicity of treatment. Radiation dose may also be important. It is essential that trials of synchronous chemotherapy report the radiation doses actually given, not simply those that were intended. If synchronous chemotherapy increases acute morbidity and necessitates the attentuation or curtailment of radiation therapy, then there may be little overall gain. Trials designed to answer these important questions need not be complex, nor should their entry criteria be too restrictive. Large simple studies are now required (Peto and Easton, 1989) to define more precisely the contribution of synchronous chemotherapy to the radiotherapeutic management of head and neck cancer.
